Long-term use of dasatinib in patients with metastatic castration-resistant prostate cancer after receiving the combination of dasatinib and docetaxel

Cancer Management and Research

Volumn 5, Issue 1, 2013, Pages 25-30

  Araujo, John C ^a   Trudel, Geralyn C ^b   Paliwal, Prashni ^b  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

Author keywords

Case study; Dasatinib; Docetaxel; Prostate cancer; Targeted therapy

Indexed keywords

BICALUTAMIDE; DASATINIB; DOCETAXEL; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; BONE TURNOVER; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; DRUG EFFICACY; DRUG RESPONSE; HUMAN; LONG TERM CARE; LYMPH NODE METASTASIS; METASTASIS; SURVIVAL TIME; TREATMENT DURATION;

EID: 84875096268     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S41667     Document Type: Article

References (19)

1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893-2917.
2. Scher HI, Sawyers CL. Biology of progressive, castration-resistant prostate cancer: directed therapies targeting the androgen-receptor signaling axis. J Clin Oncol. 2005;23(32):8253-8261.
3. Lamont KR, Tindall DJ. Minireview: Alternative activation pathways for the androgen receptor in prostate cancer. Mol Endocrinol. 2011;25(6):897-907.
4. Chen Y, Sawyers CL, Scher HI. Targeting the androgen receptor pathway in prostate cancer. Curr Opin Pharmacol. 2008;8(4):440-448.
5. Guo Z, Dai B, Jiang T, etal. Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell. 2006;10(4):309-319.
6. Asim M, Siddiqui IA, Hafeez BB, Baniahmad A, Mukhtar H. Src kinase potentiates androgen receptor transactivation function and invasion of androgen-independent prostate cancer C4-2 cells. Oncogene. 2008; 27(25):3596-3604.
7. Bristol-Myers Squibb Company. SPRYCEL® (Dasatinib) [Package Insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2012. Available from: http://packageinserts.bms.com/pi/pi_sprycel.pdf. Accessed February 5, 2013.
8. Koreckij T, Nguyen H, Brown, Yu EY, Vessella RL, Corey E. Dasatinib inhibits the growth of prostate cancer in bone and provides additional protection from osteolysis. Br J Cancer. 2009;101(2):263-268.
9. Nam S, Kim D, Cheng JQ, etal. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res. 2005;65(20):9185-9189.
10. Park SI, Zhang J, Phillips KA, etal. Targeting SRC family kinases inhibits growth and lymph node metastases of prostate cancer in an orthotopic nude mouse model. Cancer Res. 2008;68(9):3323-3333.
11. de Vries TJ, Mullender MG, van Duin MA, etal. The Src inhibitor AZD0530reversibly inhibits the formation and activity of human osteoclasts. Mol Cancer Res. 2009;7(4):476-488.
12. Araujo JC, Mathew P, Armstrong AJ, etal. Dasatinib combined with docetaxel for castration-resistant prostate cancer: Results from a phase 1-2study. Cancer. 2012;118(1):63-71.
13. NCCN [webpage on the Internet]. Clinical Practice Guidelines in Oncology-Prostate Cancer. V1.2012. Fort Washington: National Comprehensive Cancer Network; 2012. Available from: http://www.nccn.org. Accessed March 27, 2012.
14. Horwich A, Parker C, Bangma C, Kataja V; ESMO Guidelines Working Group. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21 Suppl 5:v129-v133.
15. Saad F, Hotte SJ. Guidelines for the management of castrate-resistant prostate cancer. Can Urol Assoc J. 2010;4(6):380-384.
16. Adamo V, Noto L, Franchina T, etal. Emerging targeted therapies for castration-resistant prostate cancer. Front Endocrinol (Lausanne). 2012;3:73.
17. Nelson JB, Fizazi K, Miller K, etal. Phase 3, randomized, placebo-controlled study of zibotentan (ZD4054) in patients with castration-resistant prostate cancer metastatic to bone. Cancer. 2012;118(22):5709-5718.
18. Scher HI, Jia X, Chi K, etal. Randomized, open-label phase III trial of docetaxel plus high-dose calcitriol versus docetaxel plus prednisone for patients with castration-resistant prostate cancer. J Clin Oncol. 2011;29(16):2191-2198.
19. Regeneron Pharmaceuticals, Inc. Sanofi and Regeneron Announce Regulatory and Clinical Update for ZALTRAP® (Aflibercept) [Press Release]. Tarrytown: Regeneron Pharmaceuticals, Inc; 2012. Available from: http://files.shareholder.com/downloads/REGN/0x0x557779/94df2942-a7b5-4ea1-9c17-5ba3bd98c198/REGN_News_2012_4_5_General_Releases.pdf. Accessed December 6, 2012.